MLYS

About Mineralys Therapeutics, Inc. Common Stock (MLYS) Stock

Mineralys Therapeutics, Inc. Common Stock (MLYS) closed the 2026-09-16 session at $27.73, down 4.08% versus the previous close (-1.18). The stock opened at $28.98 and traded between $27.54 and $29.09 during that session. Session trading volume was 435K shares. The volume-weighted average price (VWAP) is $27.95.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Mineralys Therapeutics, Inc. Common Stock has a market capitalization of $2.56 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MLYS is listed on the XNAS exchange. The company employs approximately 76 people. Mineralys Therapeutics, Inc. Common Stock is headquartered in RADNOR, PA. The recorded listing date is 2023-02-10.

On this page you can find market MLYS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.